Piramal Pharma cuts reliance on Chinese ingredients
In short
Piramal Pharma is reducing its use of Chinese raw materials to lower supply risk. The report says this fits a wider push by drugmakers to depend less on China for ingredients and manufacturing.
This matters for Piramal’s supply chain and for the drug sector more broadly. The report does not say how much sourcing will shift or when the change will finish.
What the reporting says
Piramal Pharma is cutting exposure to Chinese raw materials to reduce supply risk, according to the report. The move comes as global drugmakers try to lower dependence on China for pharmaceutical ingredients and manufacturing amid rising geopolitical tensions. The source does not state the size of Piramal’s sourcing change or when it will be completed.
Why it matters
Piramal Pharma is cutting exposure to Chinese raw materials to reduce supply risk. The move aligns with a broader effort by global drugmakers to reduce reliance on China for pharmaceutical ingredients and manufacturing amid geopolitical tensions. The report does not give the scale of Piramal’s sourcing change, whether costs will rise, or which products are affected.